Journal
DRUGS
Volume 81, Issue 17, Pages 2063-2068Publisher
ADIS INT LTD
DOI: 10.1007/s40265-021-01628-5
Keywords
-
Categories
Ask authors/readers for more resources
Zimberelimab is an anti-PD-1 monoclonal antibody approved for marketing in China for the treatment of relapsed or refractory classical Hodgkin's lymphoma. The development of Zimberelimab has gone through several key milestones, leading to its first approval.
Zimberelimab ((sic)(R)) is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin's lymphoma. Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin's lymphoma. This article summarizes the milestones in the development of zimberelimab leading to this first approval.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available